Newron sees more clinical development activity in 2008

Friday 28 March 2008

Newron Pharmaceuticals S.p.A. expects to increase spending on research and development in 2008 as its two lead products, safinamide and ralfinamide, progress through the clinic, and it absorbs the pipeline of Hunter-Fleming, its recent UK acquisition.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Malta